Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metaraminol is a potent sympathomimetic amine and a substituted amphetamine used primarily for the prevention and treatment of hypotension (low blood pressure), especially as a complication of anesthesia or shock. It acts mainly as an alpha-1 adrenergic receptor agonist with some indirect action by releasing norepinephrine from nerve terminals. At higher doses it may also have weak beta-adrenergic effects. Its main clinical use is to increase both systolic and diastolic blood pressure through peripheral vasoconstriction and increased cardiac contractility. Metaraminol is administered intravenously or intramuscularly for acute hypotensive states such as those due to hemorrhage, spinal anesthesia, medication reactions, surgical complications, or shock associated with brain injury. It can also be used in the management of priapism[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metaraminol.